

Review Article

Guillain-Barré Syndrome (GBS)- A Review

P Roshan Ali*, Divyam Kumar Singh, Mitta Raghavendra, K Abbulu

Department of Pharmacology, CMR College of Pharmacy, Hyderabad, Telangana India.

ARTICLE INFO

Article history:

Received 13 Sep 2019

Received in revised form 01 Oct 2019

Accepted 13 Oct 2019

doi.org/10.38111/ijapb.20190504003

Keywords:

Guillain-Barré syndrome, peripheral nervous system, plasmapheresis, respiratory and gastrointestinal infection

ABSTRACT

Guillain-Barré syndrome (GBS), a rare neurological disorder which attack self-immune system especially peripheral nervous system (PNS) and its network of nerves located outside of the brain and spinal cord. GBS has a number of recognized subtypes that have differing clinical and pathophysiological features. Most of the incidence rates of GBS reported was between 1.1/100,000/year and 1.8/100,000/year with lower rates reported in children (less than 16 years) of 0.4/100,000/year to 1.4/100,000/year. The reason for GBS though unknown but according to the Centre for Disease Control and Prevention (CDC), about two-thirds of people developed GBS post to gastrointestinal or a respiratory infection. Infectives include *Campylobacter jejuni*, Zika virus and herpes virus besides pesticides accumulation. Nerves innervating various muscles are affecting showing difficulty in response to the brain signals is one major symptom. Electrodiagnostic study and cerebrospinal liquid (CSF) estimations are the current diagnostics. Intravenous immunoglobulin G and plasmapheresis have been demonstrated to be successful in the treatment.

1. Introduction

Guillain-Barré syndrome (GBS)- a rare neurological disorder which attack self-immune system especially peripheral nervous system (PNS) and its network of nerves located outside of the brain and spinal cord. GBS is often triggered by acute gastrointestinal or respiratory infection which lead to an immune mediated response. Further antibodies which are produced to antigen react with the myelin sheath of peripheral nerves resulting in demyelination and or axonal injury^(1,2). GBS can be from very mild case with brief weakness to almost paralysis or in some cases death was reported (due to respiratory failure). Even in the most severe cases the Recovery rate is good. Although recovered subjects still experience some type of weakness. Guillain-Barré syndrome can affect both sexes equally and can affect any age (high chances in adults and older population). However more cases are recorded in males than females. GBS is estimated to affect about one person in 0.1 million population each year¹.

Variants:

GBS subjects have distinct and persistent clinical variants which do not progress to the classic pattern of sensory loss and weakness. These are

weakness without sensory signs (pure motor variant), upper limbs (pharyngeal–cervical–brachial weakness) or lower limbs (paraparetic variant), weakness limited to the cranial nerves (bilateral facial palsy with paresthesia) and the Miller Fisher syndrome (MFS) (in full signs consists of ophthalmoplegia, areflexia and ataxia). In general, GBS variants are rarely ‘pure’ and often overlap in part with the classic syndrome or show features that are typical of other variant forms².

Variants	Frequency of Occurrence (%)
Classic sensorimotor GBS	69-71
Pure motor	16
Paraparetic	7
Pharyngeal–cervical–brachial	5
Bilateral facial palsy with paraesthesias	3
Pure sensory	<1
Miller Fisher syndrome	16-Feb
Bickerstaff brainstem encephalitis	2.5

*Data indicated is the average data. Note these are not the exact data^{3,4,5}

GBS subtypes:

GBS has a number of recognized subtypes that have differing clinical and pathophysiological features:

* Corresponding author.

E-mail address: p.roshan.ali@gmail.com

One of the most common form of renal disorders prevalent from ancient times is Urolithiasis. Urolithiasis/Renal calculi/Kidney stones is defined as the formation of mineral crystal aggregates in the urinary system mainly, kidneys, (nephrolithiasis) ureters, urinary bladder. Hence the name Urolithiasis. Urolithiasis is itself a problem whereas its recurrence is serious challenge for its therapy.

Epidemiology:

Most of the incidence rates of GBS reported was between 1.1/100,000/year and 1.8/100,000/year with lower rates reported in children (less than 16 years) of 0.4/100,000/year to 1.4/100,000/year. Although rare, with an incidence of 0.4 to 2 per 100,000, Guillain-Barre syndrome (GBS) has major effects on the healthcare system. The cost of medical care for a patient with GBS has been estimated at up to \$318,966. Overall, the cost of treating patients with GBS has been estimated at \$1.7 billion dollars per year. Males are affected at a slightly higher incidence than females. Each year, it is estimated 100,000 patients worldwide would contract GBS.^{6,7}

Etiology:

The precise cause of Guillain-Barré is still unknown. According to the Centre for Disease Control and Prevention (CDC), about two-thirds of people with Guillain-Barré develop it soon after they have been sick with diarrhoea or a respiratory infection⁸. This suggests that an improper immune response to the previous illness triggers the disorder.

Campylobacter jejuni infection had associated with Guillain-Barré and also the most common bacterial microbe which causes gastrointestinal infection in the United States. It's also the most common risk factor for Guillain-Barré.

Campylobacter is often found in undercooked food, especially poultry⁹. The following infections have also been associated with Guillain-Barré:

1. *Campylobacter jejuni*¹¹
2. *Zika virus*¹³
3. *Influenza*¹⁸
4. *Herpes virus*¹⁴
5. *Pesticide*(organophosphates)¹⁷
6. *Covid-19*¹⁹

Cases due to other viruses and post-surgery have also been reported. The CDC research indicates you're more likely to get Guillain-Barré from the flu, rather than the vaccine.

2. Pathogenesis:

The exact cause of this autoimmune disorder is unknown to us. We will take a look at the most probable disease-causing agents and the pathogenesis.

Campylobacter jejuni:

C. jejuni is a microorganism to people yet it is regularly found as a commensal animal category in numerous human consumables flying creatures. Fringe nerves comprise of many engine and tactile strands and the engine filaments begin from engine neurons in the ventral horns of the spinal string and convey nerve motivations to the muscles. The tangible filaments convey nerve driving forces from the specific tactile receptors in the fringe to the spinal rope. Their cell body dwells in the dorsal root ganglia close to the spinal rope. To speed up the conduction of these nerve

motivations, a portion of these strands are wrapped by non-leading layers of myelin sheath delivered Schwann cells. Between two adjoining myelin sheaths is a hole called the hub of Ranvier, where sodium channels are concentrated. This specific structure permits nerve driving forces to recover. The myelin sheaths keep motivations from releasing endlessly and permit driving forces to bounce starting with one hub then onto the next. The nerve motivations can be proficiently directed at up to 75 m/s by the myelinated nerves. While conduction through non-myelinated neurons is more time taking. Access to the PNS by the invulnerable framework necessitates that the blood-nerve obstruction be changed. Particular endothelial cells line the veins inside the endoneurium (the connective tissue wrapping singular nerve strands inside a fringe nerve). Some portion of the blood-nerve hindrance is because of the nearness of contrarily charged sialic corrosive containing glycoconjugates in the lumen that repulse adversely charged atoms. Tight intersections between endothelial cells add to this obstruction. Section of particles around the nerve is additionally restricted by the perineurium (the connective tissue sheath encompassing a fascicle of nerve filaments in a fringe nerve). This structure comprises of layers of particular fibroblasts, each layer of which is limited by a basal lamina with tight intersections between nearby perineural cells. Nonetheless, the blood-nerve obstruction isn't as close as the blood-mind hindrance, so limited quantities of circling proteins, for example, egg whites, IgG, and exogenously directed horseradish peroxidase (none of which can enter the focal sensory system [CNS]) can get access to the endoneural space. This relative brokenness may deliver the PNS more powerless than the CNS to counter acting agent interceded messes. The blood-nerve boundary is especially defective inside the dorsal root ganglia and is out and out missing at nerve terminals in the outskirts (for instance, at the neuromuscular intersection), making these regions particularly powerless against resistant intervened assaults^{10,11}.

Herpes virus:

Herpes simplex encephalitis (HSE) is an uncommon neurological issue described by irritation of the mind (encephalitis). Basic side effects incorporate cerebral pains, fevers, tiredness, hyperactivity, as well as broad shortcoming. The turmoil may have a few side effects like those related with meningitis, for example, a hardened neck, adjusted reflexes, disarray, and additionally discourse variations from the norm. Skin sores for the most part is not found in relationship with herpes simplex encephalitis. Herpes simplex encephalitis is brought about by an infection known as herpes simplex infection (HSV) a joined herpes infection disease (CMV, EBV, HSV). Cross-reactivity between human herpes infections has been proposed in an ongoing report wherein the EBV virion glycoprotein gp85 was immunoprecipitated by antisera to HSV-1, HSV-2 and CMV a joined herpes infection contamination (CMV, EBV, HSV)^{12,13}.

Zika virus:

Pathogenesis of ZIKV is practically obscure; in any case, it is discovered that mosquito-borne flaviviruses at first recreate in dendritic cells near the inoculation site and afterward spread to lymph hubs and the blood. Despite the fact that flaviviral replication is found to happen in cell cytoplasm, contemplates recommend that ZIKV antigens can be found in core of the tainted cells. Also, irresistible ZIKV has been identified in human blood before the start of side effects. After the replication, ZIKV may circulate from the lymphatics and circulatory system to taint different organs of the body, for example, myocardium, focal sensory system, skeletal muscles and to the hatchling. The infection replication in astroglial cells and neurons in the mind of contaminated nursing mice bring about neuronal debasement,

cell invasion and easing in the cerebrum. Moreover, the proof of aggravation is found in myocardium and skeletal muscles in the contaminated mice. The neurotropism and persistence of ZIKV may clarify neurological difficulties, for example, microcephaly in innate ZIKV contamination^{14, 15, 16}.

Pesticides (Organophosphates):

Organophosphates go about as irreversible inhibitors of carboxylic esterases, the most noteworthy of which is cholinesterase and impact by restricting the dynamic locales of the chemicals. As an outcome of incitement by expanded measures of acetylcholine at the neuromuscular intersection, neurotoxicity creates. It is accounted for that organophosphates produce a trademark example of axonal degeneration, including specifically the distal bits of the long and huge axons. This axonal degeneration is communicated clinically as a symmetric, distal, sensorimotor polyneuropathy, so-called passing on back neuropathy. Spreading of central and non-terminal axonal degeneration in a somatofugal heading to include the whole distal axon is accounted for. In a large portion of the micrographs, various deteriorated nerve strands, unstructured myelin sheaths and amazingly decreased axon distance across by the winding invagination of the myelin sheath were watched. There are exceptionally meager reports of poisonous demyelination due to OPC harming. We report an instance of Guillain-Barre Syndrome (GBS) because of harmful demyelination following OPC poison¹⁷.

3. Symptoms and Diagnosis

Symptoms:

A physical or mental segment which is seen as demonstrating a condition of ailment, particularly such a component that is obvious to the patient is known as signs. Appearances of Guillain Barre Syndrome (GBS) are given underneath.

The nerves in your periphery tangible framework interface your cerebrum to the rest of your body and send signs to your muscles. The muscles won't have the alternative to respond to signals they get from your cerebrum if these nerves are hurt. The essential indication is regularly a shuddering sensation in your toes, feet, and legs. The shuddering spreads upward to your arms and fingers²⁰.

- Difficulty with eye muscles and vision
- Difficulty swallowing, talking, or gnawing
- Pricking or a shivering sensation in the hands and feet
- Pain that can be not kidding, particularly around night time
- Coordination issues and shakiness
- Abnormal heart beat/rate or circulatory strain
- Problems with osmosis just as bladder control.

These appearances can augment in control over a period of hours, days, or weeks until explicit muscles can't be used at all and, when genuine, the individual is totally paralyzed.

Diagnosis:

Analysis of GBS relies upon rehashed neurologic assessments showing an exemplary example of progressing, even engine shortcoming and decreased myotatic reflexes. Explicit changes in cerebrospinal liquid (CSF) estimations and nerve conduction considers are emphatically steady of the conclusion²¹. Lumbar cut and neurophysiology testing ought to be acted in all patients with suspected GBS. Additional testing can be utilized on an individual premise to preclude elective clarifications for GBS-like

indications presents the differential finding of the infection.

Easing back of nerve conduction happens in an expected 80 percent of patients with GBS. Electro diagnostic study results might be ordinary in up to 13 percent of patients not long after side effect beginning, however seldom stay typical on consecutive testing over the underlying long stretches of symptoms. The successive investigation discoveries rely upon the subtype and seriousness of GBS, yet they most generally show multifocal demyelinating polyneuropathy with optional axonal degeneration followed by recuperation. Rehashed electro diagnostic studies may help decide the GBS subtype and foresee prognosis. To give satisfactory information, in any event three tactile and three engine nerves ought to be tried, despite the fact that the sural nerve ought to be kept away from on the grounds that it regularly stays ordinary in GBS²².

Subjects with GBS traditionally have expanded protein levels and an ordinary white platelet check (i.e., under 10 for every mm³ [10 × 10⁶ for each L]) in CSF. Protein levels in CSF might be ordinary in early GBS, yet they are raised in 90 percent of patients before the second's over seven day stretch of symptoms. The typical CSF white platelet tally separates GBS from different irresistible, provocative, and threatening maladies. Be that as it may, GBS may deliver a raised CSF white platelet include in patients who are serologically positive for human immunodeficiency virus²³.

4. Treatment and Management:

Treatment:

GBS requires hospitalization for steady consideration and for close observing of respiratory capacity and indications of dysautonomia. Intravenous immunoglobulin G treatment and plasma trade have been demonstrated to be successful in AIDP. Utilization of steroids isn't indicated. Unfavorable visualization associates with more established age, fast beginning of extreme tetraparesis, early requirement for ventilator support, under 20 percent compound muscle activity potential, and AMSAN with going before C. jejuni disease or proof of hostile to GM1 antibodies²⁴.

Plasmapheresis:

In a meta-examination of 6 class II trails contrasting plasma trade (PE) to steady think about grown-ups with GBS, it was discovered that PE decreased the danger of creating respiratory failure. Patients treated with PE fared essentially better in the accompanying optional result measures: Time to recoup strolling without help, level of patients requiring fake ventilation, term of ventilation, full muscle quality recuperation following 1 year, and extreme sequelae following 1 year. Time to beginning of engine recuperation in somewhat influenced patients was altogether abbreviated in the PE bunch n mellow GBS, two meetings of PE are better than none. In moderate GBS, 4 meetings are better than 2. In serious GBS, 6 meetings are no superior to 4. In accordance with these discoveries, Yuki et al revealed that in any event 2 PE are expected to fundamentally decrease the coursing immunoglobulin complexes²⁷. Besides IVIg and plasma trade, no different strategies or medications have been demonstrated successful in the treatment of GBS.

IVG THERAPY/Intravenous immune globulin (IVIg):

IVIg is demonstrated to be viable, in subject incapable to walk independent, when begun inside the initial fourteen days after beginning of shortcoming. Regardless of whether the absolute IVIg portion (2 g/kg body weight) allowed in 2 days (1 g/kg every day) is more helpful than when allowed in 5 days (0.4 g/kg every day) isn't known. In our focuses, we for the most part give the all-out IVIg dose in 5 days, since this routine may instigate less symptoms and in light of the fact that youngsters who get a quicker

IVIg routine are accounted for to have treatment-related variances (TRFs) more frequently⁶.

These medicines are similarly powerful. Blending them or directing in a steady progression is not any more successful than utilizing either strategy alone.

You are likewise prone to be offered medicine to:

- Relieve torment, which can be serious
- Prevent blood clots, which can create while you're stationary

Individuals with Guillain-Barre disorder need physical assistance and treatment previously and during recuperation. Your consideration may include:

- Movement of your arms and legs via guardians before recuperation, to help keep your muscles adaptable and solid
- Physical treatment during recuperation to assist you with adapting to weariness and recover quality and legitimate development
- Training with versatile gadgets, for example, a wheelchair or supports, to give you portability and self-care skills²⁷

This investigation was attempted to underscore the viability of plasmapheresis in treatment of grown-up GBS patients and to describe strategies for diminishing the monetary weight in the treatment of these patients utilizing altered plasmapheresis. They were treated with plasmapheresis more than 10 days with REF627 unit from Haemonetics Corporation Limited on MCS+ machine. Improvement was noted by the adjustment in the incapacity scale score and costs of different methods of treatment were likewise thought of. Seventy-five percent indicated improvement toward the finish of the treatment. The expense of adjusted plasmapheresis was Rs. 8000/cycle, i.e., Rs. 40,000/patient²⁷.

Management:

Psychological:

There is a high occurrence of misery among patients with GBS. On the off chance that accessible, it is significant for the patient and their families to approach bolster gatherings. It is likewise significant that directing and mental assistance be accessible if necessary.

Gastrointestinal:

Great nourishment is significant especially for those patients with bulbar shortcoming, and the individuals who are calmed and precisely ventilated. Helpless oral admission may require induction of enteral or parenteral taking care of. Dietician input is valuable to guarantee sufficient calorific, micronutrient, liquid and electrolyte admission. Patients with autonomic brokenness might be helpless to the advancement of a disabled ileus. This might be treated with prokinetic specialists, for example, metoclopramide or erythromycin.

Rehabilitation:

40% of patients who experience the ill effects of GBS will require confirmation for inpatient recovery. Cautious consideration ought to be paid to appendage situating and act as appendage shortcoming can prompt pressure nerve paralyses, pressure injuries and contractures. Broad contribution from physiotherapists and word related advisors is basic to give custom-made fortifying activities and strong guides. Patients may likewise experience the ill effects of determined weakness, which may react to an activity program.

Prognosis:

Shy of death, the direst outcome imaginable in GBS is tetraplegia inside 24 hours, with fragmented recuperation following year and a half or more. The most ideal situation is mellow trouble strolling, with recuperation inside weeks. The standard situation, in any case, is top shortcoming in 10-14 days, with recuperation in weeks to months. Normal time on a ventilator

(without treatment) is 50 days. There are likely numerous gentle instances of GBS that are rarely completely analyzed, and patients make full recuperation without treatment. The range of milder sickness has not been all around examined nor explained.

Roughly 80% patients with GBS walk autonomously at a half year, and about 60% of patients accomplish full recuperation of engine quality by 1 year. Recuperation in around 5-10% of patients with GBS is drawn out, with a while of ventilator reliance and a deferred, fragmented recovery²⁸.

5. Conclusion

Guillain-Barré syndrome (GBS) is one of the rare autoimmune disease which mainly target neurological system. It is a changeling task in knowing the pathological reason behind the cause and also diagnosing it. Treatment with IVIg and Plasmapheresis shown to be effective. Nevertheless, only further research would give comprehensive reason behind the cause and more efficient treatment.

Acknowledgements

The authors are thankful to Chairman, Mr. Ch. Gopal Reddy, CMR College of Pharmacy, Kandlakoya (V), Medchal, Hyderabad, India.

Conflict of Interest

The author(s) confirm that this article content has no conflict of interest.

References

1. Guillain-Barre syndrome fact sheet, NINDS, Publication Year 2018, NIH Publication No 18-NS-2902.
2. Leonhard SE, Mandarakas MR, Gondim FA, Bateman K, Ferreira ML, Cornblath DR, van Doorn PA, Dourado ME, Hughes RA, Islam B, Kusunoki S. Diagnosis and management of Guillain-Barré syndrome in ten steps. *Nature Reviews Neurology*. 2019 Nov;15(11):671-83.
3. Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, Swan AV, Plasma Exchange/Sandoglobulin Guillain - Barré Syndrome Trial Group. Electrophysiological classification of Guillain - Barré syndrome: clinical associations and outcome. *Annals of neurology*. 1998 Nov;44(5):780-8.
4. Hiew FL, Ramlan R, Viswanathan S, Puvanarajah S. Guillain-Barré Syndrome, variants & forms fruste: Reclassification with new criteria. *Clinical Neurology and Neurosurgery*. 2017 Jul 1;158:114-8.
5. Wakerley BR, Kokubun N, Funakoshi K, Nagashima T, Hirata K, Yuki N. Clinical classification of 103 Japanese patients with Guillain-Barre syndrome. *Journal of the neurological sciences*. 2016 Oct 15;369:43-7.
6. Willison HJ, Jacobs BC, Van Doorn PA. Guillain-barre syndrome. *The Lancet*. 2016 Aug 13;388(10045):717-27.
7. McGrogan A, Madle GC, Seaman HE, De Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. *Neuroepidemiology*. 2009;32(2):150-63.
8. Jacquelyn Cafasso and Lauren Reed-Guy, health line, reviewed by Deborah Weatherspoon

9. Silva J, Leite D, Fernandes M, Mena C, Gibbs PA, Teixeira P. *Campylobacter* spp. as a foodborne pathogen: a review. *Frontiers in microbiology*. 2011 Sep 27;2:200.
10. Nachamkin I, Allos BM, Ho T. *Campylobacter* species and Guillain-Barre syndrome. *Clinical microbiology reviews*. 1998 Jul 1;11(3):555-67.
11. Young KT, Davis LM, DiRita VJ. *Campylobacter jejuni*: molecular biology and pathogenesis. *Nature Reviews Microbiology*. 2007 Sep;5(9):665-79.
12. Kostrzewski MS. National organization of rare disorders (NORD) web site. *Journal of Consumer Health on the Internet*. 2006 Apr 19;10(1):77-87.
13. Amzerin M, Fadoukhair Z, Belbaraka R, Iraqui M, Boutayeb S, M'rabti H, Kebdani T, Hassouni K, Benjaafar N, El Gueddari BK, Errihani H. Metastatic ameloblastoma responding to combination chemotherapy: case report and review of the literature. *Journal of medical case reports*. 2011 Dec 1;5(1):491.
14. Miner JJ, Diamond MS. Zika virus pathogenesis and tissue tropism. *Cell host & microbe*. 2017 Feb 8;21(2):134-42.
15. Moghadam SR, Bayrami S, Moghadam SJ, Golrokhi R, Pahlaviani FG, SeyedAlinaghi S. Zika virus: A review of literature. *Asian Pacific Journal of Tropical Biomedicine*. 2016 Dec 1;6(12):989-94.
16. Do Rosário MS, De Jesus PA, Vasilakis N, Farias DS, Novaes MA, Rodrigues SG, Martins LC, da Costa Vasconcelos PF, Ko AI, Alcântara LC, De Siqueira IC. Guillain–Barre syndrome after zika virus infection in Brazil. *The American journal of tropical medicine and hygiene*. 2016 Nov 2;95(5):1157-60.
17. Liu HF, Ku CH, Chang SS, Chang CM, Wang IK, Yang HY, Weng CH, Huang WH, Hsu CW, Yen TH. Outcome of patients with chlorpyrifos intoxication. *Human & Experimental Toxicology*. 2020 Apr 27:0960327120920911.
18. Vellozzi C, Iqbal S, Broder K. Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence. *Clinical infectious diseases*. 2014 Apr 15;58(8):1149-55.
19. Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: a case report. *Journal of Clinical Neuroscience*. 2020 Apr 15.
20. Head VA, Wakerley BR. Guillain–Barré syndrome in general practice: clinical features suggestive of early diagnosis. *British Journal of General Practice*. 2016 Apr 1;66(645):218-9.
21. van den Berg B, Bunschoten C, van Doorn PA, Jacobs BC. Mortality in guillain-barre syndrome. *Neurology*. 2013 Apr 30;80(18):1650-4.
22. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain - Barré syndrome. *Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society*. 1990;27(S1):S21-4.
23. Spudich SS, Nilsson AC, Lollo ND, Liegler TJ, Petropoulos CJ, Deeks SG, Paxinos EE, Price RW. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. *BMC infectious diseases*. 2005 Dec;5(1):1-9.
24. Olshansky A. Diagnosis and treatment of guillain-barre syndrome. *AMA Journal of Ethics*. 2007 Aug 1;9(8):552-4.
25. Meena AK, Khadilkar SV, Murthy JM. Treatment guidelines for Guillain–Barré syndrome. *Annals of Indian Academy of Neurology*. 2011 Jul;14(Suppl1): S73.
26. Swan AV, Van Doorn PA, Hughes RA. Intravenous immunoglobulin for Guillain-Barré syndrome. *Cochrane Database Syst Rev*. 2014;19(9).
27. Iyer RR, Shah PH, Roy SS, Suri SK. Reducing the economic burden in management of Guillain–Barre syndrome using modified plasmapheresis. *Asian journal of transfusion science*. 2016 Jul;10(2):118.
28. Tandel H, Vanza J, Pandya N, Jani P. *European Journal Of Pharmaceutical And Medical Research*.